Onyx Begins Phase II With ONYX-015

- Onyx Pharmaceuticals has initiated a Phase II clinical trial of itsanticancer agent ONYX-015, an adenovirus which kills p53-deficient cells, in combination with cisplatin and 5-fluorouracil. The trial will enroll about 30 head and neck cancer patients who are chemotherapy-naive, with enrollment expected to be completed during the first quarter of 1998. Onyx is also conducting Phase II studies of ONYX-015 as a monotherapy in patients with recurrent and refractory head and neck tumors.